220 related articles for article (PubMed ID: 24288410)
1. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
Heine A; Brossart P; Wolf D
Blood; 2013 Nov; 122(23):3843-4. PubMed ID: 24288410
[No Abstract] [Full Text] [Related]
2. Cytomegalovirus Retinitis in a Patient Who Received Ruxolitinib.
von Hofsten J; Johnsson Forsberg M; Zetterberg M
N Engl J Med; 2016 Jan; 374(3):296-7. PubMed ID: 26789901
[No Abstract] [Full Text] [Related]
3. Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis.
Kremyanskaya M; Mascarenhas J; Rampal R; Hoffman R
Br J Haematol; 2014 Oct; 167(1):144-6. PubMed ID: 24862179
[No Abstract] [Full Text] [Related]
4. Ruxolitinib: the first agent approved for myelofibrosis.
Verstovsek S
Clin Adv Hematol Oncol; 2012 Feb; 10(2):111-3. PubMed ID: 22402352
[No Abstract] [Full Text] [Related]
5. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.
Chen YH; Lee CH; Pei SN
Leuk Lymphoma; 2015 May; 56(5):1528-9. PubMed ID: 25213182
[No Abstract] [Full Text] [Related]
6. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y
Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088
[TBL] [Abstract][Full Text] [Related]
7. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.
Massa M; Rosti V; Campanelli R; Fois G; Barosi G
Leukemia; 2014 Feb; 28(2):449-51. PubMed ID: 24145312
[No Abstract] [Full Text] [Related]
8. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.
Lee SC; Feenstra J; Georghiou PR
BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24891492
[TBL] [Abstract][Full Text] [Related]
9. [Ruxolitinib prescription in myelofibrosis].
Lemal R; Robin M; Ravinet A; Cacheux V; Guièze R; Bay JO
Bull Cancer; 2013 Sep; 100(9):897-902. PubMed ID: 23985569
[TBL] [Abstract][Full Text] [Related]
10. Iatrogenic Kaposi sarcoma in a patient treated with ruxolitinib: A case report.
Tourlaki A; Benzecry V; Veraldi S; Brambilla L
J Dermatol; 2020 Feb; 47(2):e38-e39. PubMed ID: 31829460
[No Abstract] [Full Text] [Related]
11. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
Palandri F; Palumbo GA; Elli EM; Polverelli N; Benevolo G; Martino B; Abruzzese E; Tiribelli M; Tieghi A; Latagliata R; Cavazzini F; Bergamaschi M; Binotto G; Crugnola M; Isidori A; Caocci G; Heidel F; Pugliese N; Bosi C; Bartoletti D; Auteri G; Cattaneo D; Scaffidi L; Trawinska MM; Stella R; Ciantia F; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Iurlo A; Vianelli N; Cavo M; Breccia M; Bonifacio M
Blood Cancer J; 2021 Jan; 11(1):4. PubMed ID: 33414394
[No Abstract] [Full Text] [Related]
12. Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis.
Verstovsek S; Yeleswaram S; Hou K; Chen X; Erickson-Viitanen S
Hematol Oncol; 2018 Oct; 36(4):701-708. PubMed ID: 30105794
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus reactivation associated with ruxolitinib.
Shen CH; Hwang CE; Chen YY; Chen CC
Ann Hematol; 2014 Jun; 93(6):1075-6. PubMed ID: 24173089
[No Abstract] [Full Text] [Related]
14. Long-term outcome of treatment with ruxolitinib in myelofibrosis.
Tefferi A; Litzow MR; Pardanani A
N Engl J Med; 2011 Oct; 365(15):1455-7. PubMed ID: 21995409
[No Abstract] [Full Text] [Related]
15. Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib.
Fournier JB; Cummings F; Cannella J; Breen C; Zhou L; Iwamoto S
Dermatol Online J; 2014 Oct; 20(10):. PubMed ID: 25526003
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib for myelofibrosis--an update of its clinical effects.
Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
[TBL] [Abstract][Full Text] [Related]
17. Safety considerations when treating myelofibrosis.
O'Sullivan JM; McLornan DP; Harrison CN
Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
[TBL] [Abstract][Full Text] [Related]
18. Disseminated tuberculosis associated with ruxolitinib.
Hopman RK; Lawrence SJ; Oh ST
Leukemia; 2014 Aug; 28(8):1750-1. PubMed ID: 24625550
[No Abstract] [Full Text] [Related]
19. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Raza A; Vaddi K; Sun W; Peng W; Sandor V; Kantarjian H;
Haematologica; 2015 Apr; 100(4):479-88. PubMed ID: 25616577
[TBL] [Abstract][Full Text] [Related]
20. Progressive multifocal leukoencephalopathy associated with ruxolitinib.
Wathes R; Moule S; Milojkovic D
N Engl J Med; 2013 Jul; 369(2):197-8. PubMed ID: 23841743
[No Abstract] [Full Text] [Related]
[Next] [New Search]
